OBJECTIVES The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD). BACKGROUND Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase inhibitors (“statins”) may prevent cardiovascular events in patients with non–dialysis-requiring CKD, adverse d...

A spirin for primary prevention of cardiovascular disease (CVD) remains a challenging issue for clinicians, patients, and health policy makers. Even with the availability of multiple randomized trials and several high-quality systematic reviews and meta-analyses, significant debate remains about which patients, if any, should be offered aspirin for primary prevention. The main US guideline-issu...

INTRODUCTION Risk scoring is an integral part of the prevention of cardiovascular disease (CVD) and should form the basis for the decision to offer medication to reduce cholesterol (statins). However, there is a suggestion in the literature that many patients are still initiated on statins based on raised cholesterol rather than a raised CVD risk. It is important, therefore, to investigate the ...

OBJECTIVE Guidelines on primary prevention of cardiovascular disease (CVD) emphasize identifying high-risk patients for more intensive management, but patients' misconceptions of risk hamper implementation. Insight is needed into the type of patients that general practitioners (GPs) encounter in their cardiovascular prevention activities. How appropriate are the risk perceptions and worries of ...

BACKGROUND AND PURPOSE Despite the availability of risk engines to determine cardiovascular risk, risk factor control is suboptimal. Using EURIKA data we compared risk factor control in Germany with that of 11 other European countries (rest of Europe [ROE]) to identify differences and opportunities for improvement. METHODS EURIKA was a multinational, cross-sectional study in 12 European count...

Both American Diabetes Association (ADA) and College of Cardiology (ACC) guidelines recommend that patients with diabetes between the ages 40-75 years be prescribed at least a moderate-intensity statin. In all who have established atherosclerotic cardiovascular disease (CVD), high-intensity statin should implemented as secondary prevention measure. The purpose this study was to assess prescribi...

BACKGROUND It is uncertain whether multiple health behaviour change (MHBC) interventions are effective for the primary prevention of cardiovascular disease (CVD) in primary care. A systematic review and a meta-analysis were performed to evaluate the effectiveness of MHBC interventions on CVD risk and CVD risk factors; the study also evaluated associations of theoretical frameworks and intervent...

BACKGROUND Clinical care for older adults is complex and represents a growing problem. They are a diverse patient group with varying needs, frequent presence of multiple comorbidities, and are more susceptible to treatment harms. Thus Clinical Practice Guidelines (CPGs) need to carefully consider older adults in order to guide clinicians. We reviewed CPG recommendations for primary cardiovascul...

OBJECTIVE Strategies for initiating statin use among adult patients with diabetes for primary cardiovascular disease (CVD) prevention include treating all patients (assuming diabetes is a coronary risk equivalent) or treating patients who are at risk of developing CVD. The aim of the study was to combine both strategies to derive an appropriate age cutoff for prescribing statins. By considering...